| This week's sponsor is FierceBiotech Drug Development Forum. | |  | FierceBiotech 2nd Drug Development Forum - September 25-27 in Boston
90+ executive-level speakers share advanced partnership and pipeline strategies. Learn to adapt to increased deal complexity, real world evidence and digital technologies. Unequaled networking! Sign up by August 11 to save $200 on registration. |
Featured Story | | | Tuesday, July 18, 2017 As the hemophilia market builds and tensions fray, Shire has signed a new licensing deal targeting bispecific antibodies. The Ireland-based drugmaker announced a tie-up with Swiss biotech Novimmune for a worldwide license to work on a preclinical candidate for hemophilia A. |
|
|
Top Stories Tuesday, July 18, 2017 A phase 3 trial of an oral formulation of Paratek Pharmaceuticals’ antibiotic omadacycline has met its primary endpoints. The third late-phase success sets Paratek up to file for approval with the FDA, although incidence of vomiting and nausea cast a shadow over the data. Tuesday, July 18, 2017 Kleo Pharmaceuticals' new CEO Douglas Mannion has made his first play, cutting a deal with Japan's PeptiDream to step up its pursuit of immuno-oncology drug candidates. Tuesday, July 18, 2017 Abzena has licensed its prostate-specific membrane antigen (PSMA) antibodies to Telix Pharmaceuticals. Telix has committed about $65 million (€56 million) in license fees and milestone payments in return for the exclusive right to use the antibodies to guide radioactive payloads to tumors. Tuesday, July 18, 2017 Having led the digital side of clinical services as a senior-level executive at Exco InTouch and PRA Health Sciences, Steve Powell has succeeded Wendel Barr as SynteractHCR's CEO. Tuesday, July 18, 2017 Puma Biotechnology grabbed its FDA approval for neratinib, the kinase inhibitor it’s been developing for HER2-positive breast cancer, but that doesn’t mean the newly dubbed Nerlynx will be roaring onto the market. Tuesday, July 18, 2017 Check out the rest of Tuesday's news of note. Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: DocuSign When leading biopharma companies founded SAFE-BioPharma in 2005, it was with a vision of a not too distant future with major changes in the industry: the move to collaboration with many partners, make business processes fully electronic, and to take advantage of all of the benefits of online operations. Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
